Panobinostat (Farydak®) is an inhibitor of histone deacetylases (HDACs).

It was approved by the FDA in February 2015, for patients who have received prior therapy with bortezomib and an IMiD. It is usually given in combination with bortezomib and dexamethasone.

Most common side effects:
  - Diarrhea
  - Fatigue
  - Nausea
  - Pancytopenia

It carries a boxed warning about possibility of severe diarrhea and fatal cardiac events, arrhythmias, and EKG changes.